S S Whitehead
Overview
Explore the profile of S S Whitehead including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
34
Citations
1576
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pierce K, Whitehead S, Diehl S, Naro G, Carmolli M, He H, et al.
medRxiv
. 2023 Oct;
PMID: 37790382
All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue...
2.
Mahoney R, Francis D, Frazatti-Gallina N, Precioso A, Raw I, Watler P, et al.
Vaccine
. 2012 Mar;
30(32):4892-6.
PMID: 22406455
Background: A vaccine to prevent dengue disease is urgently needed. Fortunately, a few tetravalent candidate vaccines are in the later stages of development and show promise. But, if the cost...
3.
Bennett R, Gresko A, Nelson J, Murphy B, Whitehead S
J Virol
. 2011 Oct;
86(1):420-6.
PMID: 22013033
La Crosse virus (LACV) and Jamestown Canyon virus (JCV), family Bunyaviridae, are mosquito-borne viruses that are endemic in North America and recognized as etiologic agents of encephalitis in humans. Both...
4.
Blaney Jr J, Manipon G, Murphy B, Whitehead S
Arch Virol
. 2003 May;
148(5):999-1006.
PMID: 12721805
Using reverse genetics, it is possible to readily add well-defined attenuating mutations to the genome of wild type or incompletely attenuated dengue (DEN) viruses to generate vaccine candidates that exhibit...
5.
Troyer J, Hanley K, Whitehead S, Strickman D, Karron R, Durbin A, et al.
Am J Trop Med Hyg
. 2001 Nov;
65(5):414-9.
PMID: 11716092
2Adelta30 is a live dengue-4 virus vaccine candidate with a 30-nucleotide deletion in its 3'-untranslated region. To assess the transmissibility of 2Adelta30 by mosquitoes, we compared its in vivo replication...
6.
Durbin A, Karron R, Sun W, Vaughn D, Reynolds M, Perreault J, et al.
Am J Trop Med Hyg
. 2001 Nov;
65(5):405-13.
PMID: 11716091
The recombinant dengue virus type-4 vaccine candidate 2AA30 was attenuated in rhesus monkeys due to an engineered 30-nucleotide deletion in the 3'-untranslated region of the viral genome. A clinical trial...
7.
Teng M, Whitehead S, Collins P
Virology
. 2001 Nov;
289(2):283-96.
PMID: 11689051
The surface glycoproteins of viruses can play important roles in viral attachment, entry, and morphogenesis. Here, we investigated the role of the attachment G glycoprotein of human respiratory syncytial virus...
8.
Blaney Jr J, Johnson D, Firestone C, Hanson C, Murphy B, Whitehead S
J Virol
. 2001 Sep;
75(20):9731-40.
PMID: 11559806
A recombinant live attenuated dengue virus type 4 (DEN4) vaccine candidate, 2ADelta30, was found previously to be generally well tolerated in humans, but a rash and an elevation of liver...
9.
Jones K, Whitehead S, Cunningham M, Fischetti V
Infect Immun
. 2000 Nov;
68(12):7132-6.
PMID: 11083840
Archived sera (collected in 1946) from acute rheumatic fever (ARF) and untreated scarlet fever and/or pharyngitis patients were reacted with streptococcal M protein, cardiac myosin, and cardiac tropomyosin. Except for...
10.
Wright P, Karron R, Belshe R, Thompson J, Crowe Jr J, Boyce T, et al.
J Infect Dis
. 2000 Sep;
182(5):1331-42.
PMID: 11010838
A live-attenuated, intranasal respiratory syncytial virus (RSV) candidate vaccine, cpts-248/404, was tested in phase 1 trials in 114 children, including 37 1-2-month-old infants-a target age for RSV vaccines. The cpts-248/404...